These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 21888063)

  • 1. [Advances in preservative-free glaucoma drops].
    Stefan C; Pop A; Cojocaru I
    Oftalmologia; 2011; 55(2):3-6. PubMed ID: 21888063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glaucoma and ocular surface].
    Stefan C; Cojocaru I; Pop A
    Oftalmologia; 2011; 55(1):30-3. PubMed ID: 21774383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
    Baudouin C
    Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe].
    Levrat F; Pisella PJ; Baudouin C
    J Fr Ophtalmol; 1999 Mar; 22(2):186-91. PubMed ID: 10327349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review.
    Yee RW
    Curr Opin Ophthalmol; 2007 Mar; 18(2):134-9. PubMed ID: 17301615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antiglaucoma drops--with or without preservatives].
    Zemba M
    Oftalmologia; 2009; 53(2):26-30. PubMed ID: 19697836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs?
    Baudouin C
    Int J Clin Pharmacol Res; 1996; 16(1):29-41. PubMed ID: 9001927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence on ocular surface and intraocular pressure of switching from preservative-containing to preservative-free carteolol hydrochloride ophthalmic solution].
    Chikama T; Araie M; Nishida T
    Nippon Ganka Gakkai Zasshi; 2013 May; 117(5):419-26. PubMed ID: 23855234
    [No Abstract]   [Full Text] [Related]  

  • 10. [Glaucoma and dry eye. Current concepts and future perspectives].
    Steven P; Cursiefen C
    Ophthalmologe; 2013 Dec; 110(12):1155-9. PubMed ID: 24129917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
    Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
    Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Managing treatment side effects: the respective roles of the active ingredient and the preservative].
    Aptel F; Denis P; Baudouin C
    J Fr Ophtalmol; 2011 Jun; 34(6):409-12. PubMed ID: 21511364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preservative-free treatment in glaucoma: who, when, and why.
    Stalmans I; Sunaric Mégevand G; Cordeiro MF; Hommer A; Rossetti L; Goñi F; Heijl A; Bron A
    Eur J Ophthalmol; 2013; 23(4):518-25. PubMed ID: 23483513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The influence of ocular surface diseases in the management of glaucoma].
    Van Went C; Brasnu E; Hamard P; Baudouin C; Labbé A
    J Fr Ophtalmol; 2011 Apr; 34(4):230-7. PubMed ID: 21439676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The deleterious effect of certain surface active agents on the ocular surface].
    Ravet O
    Bull Soc Belge Ophtalmol; 2007; (304):145-9. PubMed ID: 17718239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservative exposure and surgical outcomes in glaucoma patients: The PESO study.
    Boimer C; Birt CM
    J Glaucoma; 2013 Dec; 22(9):730-5. PubMed ID: 23524856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How ocular surface disease impacts the glaucoma treatment outcome.
    Kaštelan S; Tomić M; Metež Soldo K; Salopek-Rabatić J
    Biomed Res Int; 2013; 2013():696328. PubMed ID: 24224176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are preservatives necessary to improve efficacy of some glaucoma drops?
    Irkec M; Bozkurt B; Mocan MC
    Br J Ophthalmol; 2013 Dec; 97(12):1493-4. PubMed ID: 24216677
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effects of preservatives in anti-glaucoma agents on the ocular surface].
    Potop V
    Oftalmologia; 2009; 53(2):92-6. PubMed ID: 19697847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.